Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient | J Antimicrob Chemother | Jun 2022
|
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020) | J Clin Microbiol | Apr 2022 | Vol 60, Issue 4
|
Metabolism, Excretion, and Mass Balance of [14C]-Rezafungin in Animals and Humans | Antimicrob Agents Chemother | January 2022 | Vol 66, Issue 1
|
Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections | Antimicrob Agents Chemother | October 2021 | Vol 65, Issue 11
|
The long-acting echinocandin, rezafungin, prevents Pneumocystis pneumonia and eliminates Pneumocystis from the lungs in prophylaxis and murine treatment models | J Fungi | September 2021 | Vol 7, Issue 9
|
Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: A case report | Open Forum Infect Dis | August 2021 | Vol 8, Issue 11
|
Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum | Microorganisms | April 2021 | Vol 9, Issue 4
|
Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia | Antimicrob Agents Chemother | February 2021 | Vol 65, Issue 3
|
Rezafungin: a novel antifungal for the treatment of invasive candidiasis | Future Microbiol | January 2021 | Vol 16, Issue 1
|
Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis – The STRIVE Trial | Clin Infect Dis | September 2020
- Erratum | Clin Infect Dis | June 2021 | Vol 73, Issue 3
|
Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species | J Fungi | August 2020 | Vol 6, Issue 3
|
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018) | Antimicrob Agents Chemother | April 2020 | Vol 64, Issue 4
|
Rezafungin In Vitro Activity against Contemporary Clinical Nordic Candida Isolates and Candida auris Determined by the EUCAST Reference Method | Antimicrob Agents Chemother | April 2020 | Vol 64, Issue 4
|
In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae | J Antimicrob Chemother | December 2019 | Vol 74, Issue 12
|
Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects | Clin Pharmacol Drug Dev | December 2019 | Vol 9, Issue 4
|
Rezafungin Treatment in Mouse Models of Invasive-Candidiasis and Aspergillosis: Insights on the PK/PD Pharmacometrics of Rezafungin Efficacy | Pharmacol Res Perspect | December 2019 | Vol 7, Issue 6
|
Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model | Antimicrob Agents Chemother | November 2019 | Vol 63, Issue 11
|
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus | Antimicrob Agents Chemother | October 2019 | Vol 63, Issue 10
|
Pharmacodynamic Evaluation of Rezafungin (CD101) Against Candida auris in the Neutropenic Mouse Invasive-Candidiasis Model Antimicrob Agents Chemother | November 2018 | Vol 62, Issue 11
|
Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species November 2018 | Vol 73, Issue 11
|
Rezafungin (CD101), a Next Generation Echinocandin. a Systematic Literature Review and Assessment of Possible Place in Therapy J Glob Antimicrob Resist | September 2018 | Vol 14
|
EUCAST reference testing of rezafungin susceptibility: impact of choice of plastic plates Antimicrob Agents Chemother | September 2019 | Vol 63, Issue 9
|
Evaluation of the Efficacy of Rezafungin, a Novel Echinocandin, in the Treatment of Disseminated Candida auris Infection Using an Immunocompromised Mouse Model J Antimicrob Chemother | August 2018 | Vol 73, Issue 8
|
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data Antimicrob Agents Chemother | June 2018 | Vol 62, Issue 6
|
Overcoming the Resistance Hurdle: PK-PD Target Attainment Analyses of Rezafungin (CD101) for Candida albicans and Candida glabrata Antimicrob Agents Chemother | June 2018 | Vol 62, Issue 6
|
Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy Blood Purif | June 2018 | Vol 46, Issue 3
|
Activity of CD101, a Long-Acting Echinocandin, Against Clinical Isolates of Candida auris Diag Microbiol Infect Dis | March 2018 | Vol 90, Issue 3
|
CD101, a Novel Echinocandin Possesses Potent Anti -Biofilm Activity Against Early and Mature Candida albicans Biofilms Antimicrob Agents Chemother | February 2018 | Vol 62, Issue 2
|
Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design Antimicrob Agents Chemother | February 2018 | Vol 62, Issue 2
|
The Future of Echinocandin Therapy J Antimicrob Chemother | January 2018 | Vol 73, Issue Suppl 1
|
In Vitro Potency and Fungicidal Activity of CD101, a Novel Echinocandin, Against Recent Clinical Isolates of Candida Spp. Diag Microbiol Infect Dis | November 2017 | Volume 89, Issue 3
|
Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters Antimicrob Agents Chemother | November 2017 | Vol 61, Issue 11
|
Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model Antimicrob Agents Chemother | October 2017 | Vol 61, Issue 10
|
CD101, a Long-Acting Echinocandin, and Comparator Antifungal Agents Tested Against a Global Collection of Invasive Fungal Isolates in the SENTRY 2015 Antifungal Surveillance Program Int J Antimicrob Agents | September 2017 | Vol 50, Issue 3
|
Pharmacokinetics of the Novel Echinocandin, CD101, in Multiple Animal Species Antimicrob Agents Chemother | April 2017 | Volume 61, Issue 4
|
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested Against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY (2014) Antifungal Surveillance Program Antimicrob Agents Chemother | March 2017 | Volume 61, Issue 3
|
CD101, a Novel Echinocandin With Exceptional Stability Properties and Enhanced Aqueous Solubility J Antibiotics | February 2017 | Volume 70, Issue 2
|
Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin With Distinctive Pharmacokinetic Properties Antimicrob Agents Chemother | February 2017 | Volume 61, Issue 2
|
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults Antimicrob Agents Chemother | February 2017 | Volume 61, Issue 2
|
Preclinical Evaluation of the Stability, Safety and Efficacy of CD101, a Novel Echinocandin Antimicrob Agents Chemother | November 2016 | Volume 60, Issue 11
|
Activity of a Long-Acting Echinocandin, CD101, Determined Using CLSI and EUCAST Reference Methods, Against Candida and Aspergillus Spp., Including Echinocandin- and Azole-Resistant Isolates J Antimicrob Chemother | October 2016 | Volume 71, Issue 10
|
Characterization of in Vitro Resistance Development to the Novel Echinocandin, CD101, in Candida Species Antimicrob Agents Chemother | September 2016 | Volume 60, Issue 10
|
CD101: a Novel Long-Acting Echinocandin Cell Microbio | September 2016 | Volume 18, Issue 9
|
